R. Hindes
Achillion Pharmaceuticals (United States)(US)
Publications by Year
Research Areas
Hepatitis C virus research, Hepatitis B Virus Studies, Liver Disease Diagnosis and Treatment, HIV/AIDS drug development and treatment, Immunodeficiency and Autoimmune Disorders
Most-Cited Works
- → Daclatasvir plus Sofosbuvir for Previously Treated or Untreated Chronic HCV Infection(2014)1,191 cited
- → Long-Term Entecavir Therapy Results in the Reversal of Fibrosis/Cirrhosis and Continued Histological Improvement in Patients with Chronic Hepatitis B†,‡(2010)980 cited
- → Nucleotide Polymerase Inhibitor Sofosbuvir plus Ribavirin for Hepatitis C(2013)754 cited
- → Entecavir for Treatment of Lamivudine-Refractory, HBeAg-Positive Chronic Hepatitis B(2006)413 cited
- → Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial(2013)328 cited
- → Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial(2013)296 cited
- → A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients(2005)248 cited
- → Entecavir therapy for lamivudine‐refractory chronic hepatitis B(2008)168 cited
- → Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial(2012)147 cited
- → Sofosbuvir and Daclatasvir Combination Therapy in a Liver Transplant Recipient With Severe Recurrent Cholestatic Hepatitis C(2013)141 cited